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ApoptosisLoss of function recessivemutations in the SLC29A3 gene that encodes human equilibrative nucleoside transporter 3
(ENT3) have been identiﬁed in patientswith pigmented hypertrichotic dermatosiswith insulin-dependent diabetes
(PHID). ENT3 is a member of the equilibrative nucleoside transporter (ENT) family whose primary function is
mediating transport of nucleosides and nucleobases. The aims of this study were to characterise ENT3 expression
in islet β-cells and identify the effects of its depletion on β-cell mitochondrial activity and apoptosis. RT-PCR
ampliﬁcation identiﬁed ENT3 expression in human and mouse islets and exocrine pancreas, and in MIN6 β-cells.
Immunohistochemistry using human and mouse pancreas sections exhibited extensive ENT3 immunostaining of
β-cells, which was conﬁrmed by co-staining with an anti-insulin antibody. In addition, exposure of dispersed
human islet cells and MIN6 β-cells to MitoTracker and an ENT3 antibody showed co-localisation of ENT3 to β-cell
mitochondria. Consistent with this, Western blot analysis conﬁrmed enhanced ENT3 immunoreactivity in β-cell
mitochondria-enriched fractions. Furthermore, ENT3 depletion in β-cells increased mitochondrial DNA content
and promoted an energy crisis characterised by enhanced ATP-linked respiration and proton leak. Finally, inhibition
of ENT3 activity by dypridamole and depletion of ENT3 by siRNA-induced knockdown resulted in increased caspase
3/7 activities inβ-cells. These observations demonstrate that ENT3 is predominantly expressedby isletβ-cellswhere
it co-localises with mitochondria. Depletion of ENT3 causes mitochondrial dysfunction which is associated with
enhanced β-cell apoptosis. Thus, apoptotic loss of islet β-cells may contribute to the occurrence of autoantibody-
negative insulin-dependent diabetes in individuals with non-functional ENT3 mutations.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Pigmented hypertrichotic dermatosis with insulin-dependent diabe-
tes (PHID) is a rare autosomal recessive disorder that is characterised
predominantly by autoantibody negative, insulin-dependent diabetes
that is associated with hyperpigmentation and hypertrichosis [1,2].
Homozygosity mapping from six patients with PHID in ﬁve unrelated
families identiﬁed ﬁve loss of function mutations in the SLC29A3 gene
that encodes human equilibrative nucleoside transporter 3 (ENT3), a
member of the equilibrative nucleoside transporter (ENT) family [3].r; MIN6 cells, mouse insulinoma
mption rate; PHID, pigmented
tes; VDAC, voltage-dependent
tional Sciences, Faculty of Life &
uilding, Guy's Campus, London
).ENTs are a widely distributed family of mammalian transporters
whose primary function is transporting nucleotide synthesis precursors,
such as nucleosides and nucleobases within cells [4,5]. There are four
ENTs, designated ENT1-4 [4,6], that inﬂuence diverse physiological
processes such as cardiovascular function and neurotransmission by
regulating intracellular adenosine trafﬁcking. The cellular uptake of
hydrophilic nucleoside analogues used in the treatment of cancers and
viral diseases (e.g. gencitabine and zidovidine) is also facilitated by
ENTs. ENT1 and 2 are ubiquitously distributed in human and rodent
tissues and their functions in nucleoside transport are relatively well-
characterised. Much less is known about the tissue distributions and
functions of ENT3, although it is reported to be expressed by several
mouse and human tissues such as placenta, where the cDNA was origi-
nally cloned, heart, where it functions as a pH-dependent lysosomal
transporter [7,8] and most recently neurons and astrocytes, where it is
thought to mediate adenosine transport [9].
Human ENT3 (hENT3) is a 475-residue protein that is 74% identical
in amino acid sequence to its mouse homologue mENT3 [7,8]. Unlike
ENT1 and ENT2, the nucleoside transport function of ENT3 is maximal
at pH 5.5, suggesting that it may be localised to acidic intracellular
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quences possess a 51 residue hydrophilic N-terminal region containing
two dileucine motifs that are characteristic of endosomal/lysosomal
targeting sequences [6,10], so it has been suggested that ENT3 is localised
to lysosomes rather than sharing the cell surface distribution of ENT1 and
ENT2 [7]. However, a more recent study has identiﬁed a putative mito-
chondria targeting signal at the N-terminus of hENT3 and demonstrated
that hENT3 is predominantly expressed by mitochondria in human
hepatocytes, where it regulates transport of native nucleosides and
nucleoside drugs [11]. A mitochondrial adenosine transport sys-
tem, distinct from the mitochondrial adenine nucleotide carrier, has
previously been identiﬁed in rat testis [12] supporting the observations
[11] that adenosine transport by mitochondria is of physiological
relevance.
Given the essential role of mitochondria in regulating cellular
metabolism and cell survival, it is possible that the development of
diabetes in individuals with PHID arises, at least in part, through
impaired β-cell mitochondrial ENT3 activity resulting in metabolic
defects and apoptotic loss of β-cells. To date, there have been no
experimental evaluations of mammalian ENT3 expression and sub-
cellular localisation in islets, so this study was designed to charac-
terise ENT3 expression by human and mouse β-cells and identify
the effects on mitochondrial bioenergetics and β-cell apoptosis
following ENT3 depletion.
2. Materials and methods
2.1. Materials
Dulbecco's modiﬁed eagle's medium (DMEM), Research Park Memo-
rial Institute (RPMI)medium, penicillin/streptomycin, L-glutamine, colla-
genase type XI, cell dissociation solution, DAPI (4′,6-Diamidino-2-
phenylindole), oligomycin, rotenone, antimycin A, mitochondria isola-
tion kit (MITOISO2), anti-β-actin antibody and anti-glucagon antibody
were purchased from Sigma-Aldrich (Dorset, UK). Dipyridamole was
obtained fromTocris Biosciences (Bristol, UK).MitoTracker red CMXRos,
foetal bovine serum (FBS) and 10% polyacrylamide bis–tris gels were
from Invitrogen (Paisley, UK). ECL Western blotting detection reagents
and Rainbow™ molecular weight markers were supplied by GE
Healthcare (Buckinghamshire, UK). RNeasy mini kits, DNeasy blood
and tissue kits, RNase-free DNase sets and QuantiTect SYBR® Green
PCR Kits were obtained from Qiagen (Manchester, UK). Primers that
were used for both standard PCR andquantitative PCRwere fromOperon
Biotech (Cologne, Germany). Standard PCR was carried out using a Px2
Thermal RT-PCR cycler (Thermo Scientiﬁc, Epsom, UK) and quantitative
PCR was performed using a LightCycler480 (Roche Diagnostics, West
Sussex, UK). The goat polyclonal antibody, raised against a synthetic
peptide sequence near the N terminus of SLC29A3 (ENT3) that is
not present within ENT2 or ENT1, was purchased from Santa Cruz
(Cambridgeshire, UK), the anti-insulin antibody was from Dako UK
Ltd. (Cambridgeshire, UK), the voltage-dependent anion channel
antibody was from Cell Signaling Technology, Inc. (Massachusetts,
USA), Pierce bicinchoninic acid (BCA) protein assay kits, horseradish
peroxidase-linked anti-rabbit secondary antibody and Texas Red-
and FITC-conjugated secondary antibodies were from Thermo Scientiﬁc
(Surrey, UK), as were scrambled non-silencing siRNAs, ON-TARGETplus
SMARTpool Slc29a3 siRNAs, Accell green ﬂuorescent nontargeting
control siRNAs, and Accell SMARTpool Slc29a3 siRNAs. Nucleofector
Kit R for MIN6 cell transfection was from Amaxa Biosystems (Cologne,
Germany). Caspase-Glo 3/7 and CellTiter-Glo assay kitswere purchased
from Promega (Southampton, UK). Recombinant murine tumour necro-
sis factor α (TNFα), interferonγ (IFNγ) and interleukin-1β (IL-1β) were
from PeproTech EC (London, UK). All materials and reagents for the
extracellular ﬂux (XF) assays were obtained from Seahorse Biosciences
(Copenhagen, Denmark). ICR mice were purchased from Harlan
(Oxfordshire, UK).2.2. Isolation of mouse and human islets
Islets of Langerhanswere isolated frommale ICRmice by collagenase
digestion of the exocrine pancreas, essentially as described previously
[13]. Human islets of Langerhans and acinar cellswere aseptically isolat-
ed from pancreases from non-diabetic, heart beating cadaver organ
donors at King's College Hospital Islet Transplantation Unit with appro-
priate ethical approval [14].
2.3. RT-PCR
RNAswere extracted fromMIN6 β-cells, mouse and human islets and
mouse andhuman acinar cells according to theRNeasy kitmanufacturer's
protocol and reverse-transcribed into cDNAs as described previously [15].
cDNAs were then ampliﬁed over 40 cycles using synthetic oligonucleo-
tide primers speciﬁc for mouse ENT1 (sense: 5′-ccagtggttctgagctgtca-3′;
antisense: 5′-ctgttggtgggtggagagtt-3′; 241 bp product), ENT2 (sense: 5′-
gctgggtaccatgccttcta-3′; antisense: 5′-ccacacagggtgtgatgaag-3′; 152 bp
product), ENT3 (sense: 5′-ttgggctctgtatgggactc-3′; antisense: 5′-
ttcttcaggatgggtccaag-3′; 190 bp product) and human ENT3 (sense:
5′-atgaccggctcctttcctat-3′; antisense: 5′-atgcagagcacgaggaagat-3′;
170 bp product). For some analyses, quantitative PCR was performed
using the same primers that were used in the standard PCR. Relative
expression of mRNAs was determined after normalisation against β-
actin as an internal reference and calculated by the 2−ΔΔCt method
[16].
2.4. Immunohistochemistry
Mouse and human pancreases were ﬁxed in 4% paraformaldehyde,
wax embedded, and 5 μm sections were cut onto microscope slides.
Dewaxed and rehydratedmouse pancreas sectionswere incubated over-
night at 4 °C with ENT3 antibody alone (1/50 dilution) and human pan-
creas sections were co-incubated with antibodies directed against ENT3
and insulin (both at 1/50 dilution). Immunoreactive ENT3 in mouse
sections was detected by incubation with streptavidin–horseradish
peroxidase and diaminobenzidine, and with a FITC-conjugated second-
ary antibody (1/50dilution) inhuman sections. Insulin immunoreactivity
in human pancreas was detected by incubation with a Texas Red-
conjugated secondary antibody (1/50 dilution). Immunostained pancre-
as sections were visualised under a Nikon TE2000-Umicroscope, images
were acquired with a Nikon Digital Sight-Qi1Mc camera and analysed
with the NIS-Elements Br 3.0 software.
2.5. Immunocytochemistry
MIN6 β-cells were retrieved by trypsinisation and isolated human
islets were dispersed into cell suspensions by incubating for 10 min at
37 °Cwith cell dissociation solution. These cell suspensionswere seeded
onto glass coverslips (30,000 cells/coverslip) and exposed to 200 nM
MitoTracker red CMXRos for 30 min, ﬁxed with 4% formaldehyde and
permeabilised with 0.1% (v/v) Triton X-100 in PBS. ENT3 immunoreac-
tivitywas detected by incubating overnightwith ENT3 antibody followed
by incubation with a FITC-conjugated secondary antibody (both at 1/50
dilution). Nuclei were visualised by staining cells with DAPI (0.5 μg/ml).
Immunostained cells were visualised using a Nikon TE2000-U micro-
scope (MIN6 cells, 40× objective under oil immersion) or a Leica TCS
SP2 laser scanning spectral confocal microscope (human islet cells, 63×
objective under oil immersion).
2.6. Preparation of mitochondria-enriched fractions from MIN6 β-cells
Mitochondria-enriched fractions were prepared using a commercial
mitochondria isolation kit. Brieﬂy, 2 × 107MIN6 cells werewashedwith
PBS and resuspended in 1ml cell lysis buffer for 5min. An aliquot of this
lysate was removed and used as the “crude lysate” fraction. Thereafter,
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nitol, 70 mM sucrose, 1 mM EGTA, 2 mg/ml BSA) supplemented with
protease inhibitors (104 mM AEBSF, 80 μM aprotinin, 4 mM bestatin,
1.4 mM E-64, 2 mM leupeptin and 1.5 mM pepstatin A, all provided as
a single reagent in the mitochondria isolation kit) was added to the
remaining cell lysate followed by centrifugation (1000 rpm, 10 min) to
pellet unbroken cells and nuclei. The supernatant was then centrifuged
at 11,000 rpm for 10 min and the pellet, containing mitochondria, was
resuspended in 100 μl CellLytic M lysis reagent (provided in the mito-
chondria isolation kit).2.7. SDS-PAGE/Western blotting
Protein extracts obtained from whole MIN6 β-cells and MIN6 β-cell
crude lysate and mitochondria-enriched fractions were quantiﬁed by
BCA protein assay. They were then fractionated by electrophoresis on
10% polyacrylamide gels and transferred to polyvinylidene ﬂuoride
membranes. ENT3 expression was detected by Western blotting with a
goat anti-ENT3 antibody (1/200 dilution) and a horseradish peroxidase-
linked anti-goat secondary antibody (1/7500 dilution).β-actin expression
was determined in the same samples (1/250 and 1/5000 dilutions of the
primary antibody and a horseradish peroxidase-linked anti-mouse
secondary antibody, respectively) and ENT3 expression relative to β-
actin was quantiﬁed by densitometric scanning using the Syngene
GeneTools image analysis software. Enrichment ofMIN6β-cellmitochon-
dria was determined by immunoprobing protein extracts with an anti-
body directed against the mitochondrial voltage-dependent anion
channel, VDAC (1/500 dilution) and a horseradish peroxidase-linked
anti-rabbit secondary antibody (1/5000 dilution).2.8. SiRNA-mediated ENT3 knockdown
MIN6 cells were transiently transfected with the ON-TARGETplus
SMARTpool Slc29a3 siRNAs, which are a mixture of 4 individual siRNAs
targeting ENT3 (each at 100 nM), using the AMAXA nucleofection
system according to the manufacturer's instructions. For ENT3 knock-
down in islets, groups of 250 islets were brieﬂy exposed to cell dissoci-
ation solution to allow access of the siRNAs to cells within the islets,
then exposed to 1 μM of the Accell SMARTpool Slc29a3 siRNAs. Control
MIN6β-cells andmouse isletswere transiently transfectedwith 100 nM
scrambled non-silencing siRNAs and 1 μM Accell green ﬂuorescent
nontargeting control siRNAs respectively and maintained under the
same conditions as the ENT3 siRNAs-treated cells and islets. The
transfected cells and isletswere transferred to appropriate culture vessels
followed by maintenance in a humidiﬁed incubator (37 °C, 95% air/5%
CO2) before being harvested for protein analysis by western blotting
(24–36 h of incubation), or for ATPmeasurements, monitoring of cellular
bioenergetics, caspase 3/7 assays, mitochondrial DNA (mtDNA) quantiﬁ-
cation and static insulin secretion experiments (40 h of incubation).2.9. Mitochondrial DNA content
Total genomic DNA from MIN6 β-cells that had been transfected
with scrambled siRNAs or ENT3 siRNAs for 40 h was extracted using
the DNeasy blood and tissue kit and pre-treated by sonication for
10 min to remove dilution bias [17]. MtDNA content was assessed as
the mitochondrial to nuclear genome ratio by real-time quantitative
PCR using absolute quantiﬁcation of a unique mitochondrial region
(sense: 5′-CTAGAAACCCCGAAACCAAA-3′; antisense: 5′-CCAGCTATCA
CCAAGCTCGT-3′; 125 bp product) relative to the nuclear gene Beta 2
microglobulin (B2M, sense: 5′-ATGGGAAGCCGAACATACTG-3′; anti-
sense: 5′-CAGTCTCAGTGGGGGTGAAT-3′; 177 bp product) as described
elsewhere [17].2.10. Measurements of ATP generation
MIN6 β-cells were transiently transfected with scrambled
siRNAs or ENT3 siRNAs and ATP generation was measured after
40 h using the CellTiter-Glo luminescent assay following the
manufacturer's instructions.
2.11. Cellular Bioenergetics
MIN6 β-cells that had been transiently transfected with non-
silencing siRNAs or ENT3 siRNAs were seeded onto 96-well ﬂux plates
at a density of 40,000 cells/well for 40 h then washed and equilibrated
for 1 h with an assay medium supplemented with 5 mM glucose and
1 mM sodium pyruvate. Cellular bioenergetics were then determined
using the Seahorse extracellular ﬂux analyser (XFe96) with the XF cell
Mito stress kit. Brieﬂy, basal oxygen consumption rate (OCR) was mea-
sured to establish the resting levels of mitochondrial respiration. Cells
were then treated with an ATP synthase blocker (oligomycin; 1 μM)
to determine respiration used for ATP turnover and this was followed
by treatment with a mixture of rotenone and antimycin A (both at
1 μM) to inhibit mitochondrial respiration and allow measurement
of non-mitochondrial respiration. OCR values were normalised to total
protein/well using the BCA protein assay and corrected for non-
mitochondrial respiration [18,19].
2.12. Apoptosis
MIN6 β-cells growing on 96-well plates (30,000 cells/well) were
maintained for 24 h at pH 5.5, the optimal pH for ENT3 function, in
the absence or presence of a cytokine cocktail (0.05 U/μl IL-1β, 1 U/μl
TNFα and 1 U/μl IFNγ). Some experiments were carried out in the
presence of a non-selective ENT inhibitor dipyridamole (10 μM),
and in others ENT3 was depleted from MIN6 β-cells or mouse islets
for 16 h by transient transfection with ENT3 siRNAs. Cells and islets
were then incubated in the absence or presence of the cytokine cocktail
for a further 24 h. Apoptosis was determined bymeasuring caspase 3/7
activities using the Caspase-Glo 3/7 luminescent assay following the
manufacturer's instructions.
2.13. Insulin secretion
Groups of three islets that hadbeen exposed to ENT3 siRNAs or green
ﬂuorescent nontargeting control siRNAs for 40 h were pre-incubated in
a physiological salt solution [20] containing 2 mM glucose for 2 h at
37 °C. Islets were then incubated in the presence of 2 mM glucose,
20 mM glucose or 20 mM glucose plus 500 nM of 4β phorbol myristate
acetate (PMA) for 1 h, after which samples of the supernatant were
removed for quantiﬁcation of insulin by radioimmunoassay [21].
2.14. Statistical analyses
Numerical data are expressed as means ± SEM of multiple experi-
ments. All statistical comparisons were made by Student's t tests, two-
way ANOVA or Mann–Whitney tests, as appropriate. Statistical signiﬁ-
cance was assumed at p b 0.05.
3. Results
3.1. Expression of ENT3 by mouse and human β-cells
It can be seen from Fig. 1A (upper panel, left) that PCR ampliﬁcations
with primers for mouse ENT3 produced a product of the expected size
(190 bp) using cDNA templates derived from MIN6 β-cells (lane 1),
mouse islets (lane 2) and mouse acinar cells (lane 4). However, as
expected, no products were ampliﬁed using non reverse-transcribed
RNAs extracted from mouse islets (lane 3) and acinar cells (lane 5).
Fig. 1.A: Products of RT-PCRusing primers formouse (upper panel) and human (lower panel) ENT3 (left) or ENT1 (right,mouse heart lane 1;MIN6β-cells lane 2)were electrophoretically
separated on 1.8% agarose gels. ENT3 amplicons of the correct sizeswere ampliﬁed from cDNAs obtained fromMIN6 β-cells (upper, lane 1),mouse islets (upper, lane 2),mouse acinar cells
(upper, lane 4), human heart (lower, lane 1), human islets (lower, lane 2), β-cell enriched human islets (lower, lane 3) and human acinar cells (lower, lane 4). Non reverse-transcribed
mouse islet (upper, lane 3) and acinar cell (upper, lane 5) RNAs or H2O (lower, lane 5)were used as negative controls. B:Wax-embedded sections ofmouse pancreaswere immunoprobed
with an antibody directed against ENT3 and immunoreactivity was detected using an HRP-conjugated secondary antibody in the presence of diaminobenzidine. The left panel
demonstrates that ENT3 is predominantly expressed by islet cells, with lower expression in the exocrine pancreas. The right panel shows the absence of immunostaining in a pancreas
section incubated only with the secondary antibody. C: Wax-embedded sections of human pancreas were immunostained with antibodies directed against ENT3 and insulin, and
immunopositive cellsweredetectedusing secondary antibodies conjugated to FITC (ENT3) or Texas Red (insulin). Themerged image indicates the localisation of ENT3 in insulin-expressing
β-cells in human islets.
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was used as a positive control (Fig. 1A upper panel, right), but ENT2
mRNA was not detected in MIN6 cells. As shown in Fig. 1A (lower
panel), primers for human ENT3 produced single PCR products of
170 bp with cDNAs from human heart (lane 1), human islets (lane 2),
a β-cell-enriched human islet preparation (lane 3), and a low level of
expression was also evident when human acinar cell cDNA was used
as the template (lane 4). In addition, no products were ampliﬁed
using H2O as a negative control (lane 5). Sequencing of amplicons con-
ﬁrmed that there was 100% homology between predicted sequences
and those of the ampliﬁed mouse and human products.
To determine whether ENT3 RNAs were translated into protein in
mouse and human pancreas and to examine the cellular localisation of
ENT3, immunohistochemical analysis of pancreas sections was carried
out. Fig. 1B (left panel) shows immunostaining of ENT3 in mouse
pancreas, where it can be seen that it is abundantly expressed by islet
cells, with much less immunoreactivity identiﬁed in the exocrine
pancreas, indicating a predominant localisation of ENT3 tomouse islets.
A section stained only with an HRP-conjugated secondary antibody
(right panel) indicated no islet immunostaining, as expected. To further
investigate the localisation of ENT3 immunoreactivity in the mixed cell
populations ofwhole islets,wax-embedded sections of humanpancreas
were double-stained with antibodies directed against ENT3 (Fig. 1C;
green) and insulin (Fig. 1C; red), which demonstrated that ENT3 was
present in insulin-expressing human β-cells. Some ENT3-positive,insulin-negative (green) islet cells are evident in the merged image,
indicating that ENT3 is not exclusively expressed by islet β-cells. In
addition, there were some ENT3 immunoreactive cells in the exocrine
pancreas, although ENT3 expression by acinar cells was considerably
less abundant than in the endocrine pancreas.
3.2. Co-localisation of ENT3 with mitochondria in β-cells
Following identiﬁcation of ENT3 expression by islet β-cells, as
described above, further experiments were designed to investigate the
subcellular localisation of ENT3 in β-cells. MIN6 β-cells grown on glass
coverslips were incubated with MitoTracker CMXRos (MitoTracker), a
mitochondria-speciﬁc ﬂuorescent dye, to identify mitochondria in
these cells. After formaldehyde-ﬁxation and acetone-permeabilisation,
MIN6 β-cells were then incubated with the ENT3 antibody and also
with DAPI to visualise nuclei. It can be seen that MitoTracker labelling
was observed in the cytoplasm surrounding DAPI-stained nuclei, as
expected (Fig. 2A). ENT3 immunoreactivity was observed in the cyto-
plasm, and an overlay of the images revealed co-localisation of ENT3
immunoreactivity and MitoTracker staining in MIN6 β-cells (Fig. 2A
and arrows in panels i and iii), indicating ENT3 localisation to β-cell
mitochondria. This was conﬁrmed by detection of ENT3 immunoreac-
tivity in mitochondria-enriched fractions prepared from MIN6 β-cells,
as shown in Fig. 2B. In these experiments equivalent amounts of protein
(50 μg) from MIN6 cell crude lysate and a MIN6 cell mitochondria-
Fig. 2. A: MIN6 β-cells grown on glass coverslips were incubated with MitoTracker before being ﬁxed and incubated with an ENT3 antibody. The panels show MIN6 β-cells stained with
MitoTracker (i, mitochondria), DAPI (ii, nuclei) and ENT3 (iii). Arrows in panels i and iii, and the merged image (iv) demonstrate co-localisation of ENT3 to β-cell mitochondria. B: 50 μg of
MIN6β-cell crude lysate (lane 1) and50 μg ofMIN6β-cellmitochondria-enriched fraction (lane 2)were separated on a10%polyacrylamide gel andENT3 andVDACexpression in these samples
wasdetectedbyWesternblot analysis. C:Dispersedhuman islet cells adherent onglass coverslipswere incubatedwithMitoTracker (i) before beingﬁxed and incubatedwith an insulin antibody
(ii), to identify β-cells, and with an ENT3 antibody (iii). The merged images (iv) demonstrate co-localisation of ENT3 to mitochondria in insulin-expressing human β-cells.
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and ENT3 expression in these preparations was measured by Western
blot analysis using the same ENT3 antibody that had been used for
immunohistochemistry. In addition, membranes were immunoprobedfor the mitochondrial voltage-dependent anion channel, VDAC, shown
in the lower panel of Fig. 2B. With 50 μg of total MIN6 cell crude lysate
there was little expression of ENT3 (lane 1, upper panel), and VDAC
immunoreactivity was not detectable in this lysate (lane 1, lower panel).
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mitochondria-enriched fraction (lane 2), consistent with the mitochon-
drial localisation of ENT3 identiﬁed by the immunohistochemical staining
shown in Fig. 2A.
Dispersed human islet cells were also stained with MitoTracker,
then incubated with antibodies directed against insulin and ENT3 to
determine whether ENT3 was also present in human islet β-cell mito-
chondria. Consistent with the observations in mouse MIN6 β-cells,
ENT3 immunoreactivity was found closely associated with mitochon-
dria labelled with MitoTracker in insulin-expressing human islet β-
cells (Fig. 2C).3.3. Depletion of β-cell ENT3 expression by siRNAs
The speciﬁc role of ENT3 in β-cells was investigated by transiently
transfecting MIN6 β-cells with synthetic ON-TARGETplus SMARTpool
Slc29a3 siRNAs, which are a mixture of four individual siRNAs targeting
ENT3, provided as a single reagent. Control cells were transfected with
non-silencing siRNAs. The extent of depletion was determined by
examining ENT3 protein expression in these cells relative to β-actin
expression in the same samples. It can be seen from the western blots
in Fig. 3A and densitometric quantiﬁcations in Fig. 3B that exposure to
siRNAs for 24 h did not affect ENT3 protein expression, but there was
a 59% decrease in its expression 36 h after transfection. The conse-
quences of ENT3 depletionwere therefore examined 40 h after transfec-
tion. Under the conditions where ENT3 was depleted from β-cells by
treatmentwith siRNAs therewere no changes in expression of the relat-
ed nucleoside transporter, ENT1, as shown in Fig. 3C.Fig. 3. A: Western blotting for ENT3 (upper panel) and β-actin (lower panel) expression
by MIN6 β-cells 24 h and 36 h after transfection with scrambled siRNAs (control) or
siRNAs directed against ENT3 (ENT3 siRNA). B: Densitometric quantiﬁcation of ENT3
expression relative to β-actin following exposure ofMIN6 cells for 24 h or 36 h to scrambled
siRNAs (black bars) or siRNAs directed against ENT3 (grey bars). C: Quantiﬁcation of ENT1
mRNA relative to β-actin following exposure of MIN6 cells for 36 h to scrambled siRNAs
(black bar) or siRNAs directed against ENT3 (grey bar).3.4. Depletion of ENT3 increases β-cell mtDNA content and impairs
mitochondrial function
Mitochondria contain their own DNA genome and changes in
mtDNA content have been proposed as a biomarker of mitochondrial
dysfunction [17,22,23]. Mitochondrial nucleoside transport via ENTs
may be important in mitochondrial DNA synthesis and repair so exper-
imentswere performed to investigate if ENT3 depletion affectedmtDNA
content. It can be seen from Fig. 4A thatMIN6β-cells inwhich ENT3had
been depleted by siRNA-induced knockdown for 40 h showed a signiﬁ-
cant increase in mtDNA content, as evidenced by a 1.7-fold increase in
levels ofmitochondrial DNA relative to the nuclear geneB2M [17,24,25].
MIN6 cell oxygen consumption rate (OCR) was measured using the
Seahorse XF analyser to assess β-cell mitochondrial function following
ENT3 depletion. MIN6 β-cells in which ENT3 expression was inhibited
showed a 1.5-fold increase in basal OCR. An ATP synthase blocker,
oligomycin, was used to block mitochondrial respiration used for ATP
production (ATP-linked OCR) and this parameter was increased by
1.4-fold when ENT3 was depleted, indicating that there was a higher
energy demand in these cells (Fig. 4B). In addition, signiﬁcantly higher
levels of proton leak (1.3-fold) were observed following ENT3 deple-
tion, suggesting reduced mitochondrial efﬁciency (Fig. 4B). Oxygen
consumed in other intracellular processes that are not associated
with mitochondrial respiration was determined by exposing MIN6
cells to a mixture of rotenone (inhibitor of complex I) and antimycin
A (blocker of complex III) to completely block mitochondrial respira-
tion. It was found that non-mitochondrial respiration was also
increased signiﬁcantly following ENT3 depletion (Fig. 4B), suggest-
ing an increase in the activity of cellular oxidases that are linked to
cytosolic reactive oxygen species (ROS) production [26,27]. Consis-
tent with impaired mitochondrial function following ENT3 deple-
tion, MIN6 β-cells exposed to ENT3 siRNAs for 40 h showed a small
but signiﬁcant reduction in ATP synthesis (control: 828 ± 26 × 103
luminescence units; ENT3 siRNA: 751 ± 20 × 103 luminescence
units; n = 8; P b 0.05).3.5. Effects of inhibition and depletion of ENT3 on β-cell apoptosis and
insulin secretion
In addition to energy production, mitochondria play a crucial role in
regulating cell death pathways, and dysfunction of mitochondria causes
apoptotic cell death. Experiments were thus performed to investigate
if inhibition of ENT3 affects β-cell apoptosis, and since ENT3 shows
maximal activity under acidic conditions [6] these experiments were
performed at pH 5.5. Maintaining the MIN6 β-cells at pH 5.5 did not
affect basal or cytokine-induced apoptosis, with comparable caspase
3/7 activities to those seen in our earlier experiments with MIN6 β-
cells performed at pH 7.4 [28]. In addition, western blotting of MIN6 cell
extracts after exposure to mixed cytokines for 24 h indicated that cyto-
kine treatment did not induce changes in ENT3 expression (optical densi-
ty ratio of ENT3/β-actin, control: 0.068; cytokine-treated: 0.066).MIN6β-
cells that had been incubated for 24 h with dipyridamole, an ENT inhibi-
tor, demonstrated a small yet signiﬁcant (P b 0.05) increase in the low,
Fig. 4. A: Mitochondrial DNA content of MIN6 β-cells that had been transfected with non-silencing scrambled siRNAs (black bar) or ENT3 siRNAs (grey bar) was determined by qPCR
ampliﬁcation of mitochondrial DNA which was then normalised to the nuclear gene B2M. Signiﬁcantly higher mitochondrial DNA content was observed following depletion of ENT3.
Mean + SEM, n = 6, ***P b 0.001. B: A seahorse extracellular ﬂux analyser (XFe96) and XF cell Mito stress kit was used to quantify basal and ATP-linked respiration, as well as proton leak
and non-mitochondrial respiration, inMIN6β-cells that had been transfectedwith non-silencing scrambled siRNAs (black bars) or ENT3 siRNAs (grey bars).Mean+SEM, n=15, ***P b 0.001.
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mixed cytokines on MIN6 β-cell caspase-3/7 activities were also signif-
icantly enhanced by the presence of dipyridamole (Fig. 5A). These
observations are consistent with ENT3 playing an anti-apoptotic role
in β-cells, but should be interpretedwith caution because dipyridamole
does not fully inhibit ENT3 activity, and it also inhibits othermembers of
the ENT family [29–31], including ENT1, which was also detected in
MIN6 β-cells (Fig. 1A).
To investigate the speciﬁc role of ENT3 in β-cell apoptosis its expres-
sion was down-regulated by transiently transfecting MIN6 β-cells with
ENT3 siRNAs. It can be seen from Fig. 5B that MIN6 β-cells in which
ENT3 had been depleted by siRNA-induced knockdown for 40 h showed
increased apoptosis in response to cytokines, similar to the data obtained
in the presence of dipyridamole (Fig. 5A). Similar results were obtained
when ENT3 was down-regulated in mouse islets by siRNAs treatment,
which produced a signiﬁcant increase in cytokine-induced islet cell
caspase 3/7 activities (Fig. 5C), further conﬁrming a regulatory role
of ENT3 in β-cell apoptosis.
The effects of knocking downENT3 inmouse islets (Fig. 6A) on insulin
secretory responses to glucose and the PKC activator PMA were also
investigated. It can be seen from Fig. 6B that depletion of ENT3 was
without signiﬁcant effect on basal or glucose-stimulated insulin secretion,
nor on the potentiation of insulin release by PMA.
4. Discussion
Loss of function mutations in SLC29A3, the gene encoding ENT3, are
linked to pigmented hypertrichotic dermatosis with insulin-dependent
diabetes (PHID), H syndrome, Faisalabad histiocytosis and Rosai–
Dorfman disease, all of which are autosomal recessive disorders with
histiocytic inﬁltration [1,32–34]. Recent studies using mice in which
ENT3 was globally deleted suggested that the histiocytosis in thesesyndromes was due to disrupted apoptotic cell clearance, lysosomal
defects and macrophage accumulation [35]. The mechanisms underly-
ing the diabetes phenotype in individuals with PHID have not been
established, and the reduced lifespan of ENT3 knockout mice [35]
means that they are not an ideal model for deﬁning how ENT3 disruption
contributes to β-cell loss and hypoinsulinaemia. The current study there-
fore used in vitro techniques to characterise ENT3 expression by β-cells,
and identify the effects of ENT3 depletion on β-cell mitochondrial func-
tion and apoptosis.
We have demonstrated, for the ﬁrst time, that ENT3 is expressed by
both mouse and human pancreas, with a higher abundance in islets
than in pancreatic exocrine tissue. In the endocrine pancreas ENT3 co-
localises with insulin-producing β-cells, which is consistent with the
clinical features of ENT3mutations in PHIDwhere patients require insu-
lin therapy due to β-cell failure [2,3]. Expression of ENT3 by pancreatic
acinar cells, as observed here, may play a role in the exocrine pancreatic
deﬁciency observed in some PHID cases [2] but this is not a consistent
feature of PHID,whereas insulin-dependent diabetes has been observed
in over 80% of children with PHID [1].
PHID shares features of the clinical manifestations encountered in
mitochondrial and lysosomal disorders [33], and ENT3 possesses an
endosomal/lysosomal targeting dileucine motif [6,7] and a putative
mitochondria targeting signal [11]. An intracellular localisation is
supported by observations that mutation of the dileucine to alanine
causes ENT3 to relocate to the cell surface [7], although a cell surface
localisation of native ENT3 has been demonstrated in human placental
tissues, suggesting that cellular localisation of ENT3 may be cell-type
dependent [11]. In the current study incubation of mouse and human
β-cells with a mitochondria-speciﬁc ﬂuorescent dye and an anti-ENT3
antibody indicated that ENT3 is localised to these organelles in β-cells,
an observation that was conﬁrmed by Western blotting of a β-cell
mitochondria-enriched fraction.
Fig. 5. A: MIN6 β-cells were maintained for 24 h in the absence or presence of a cytokine
cocktail, and exposed to 10 μMof thenon-selective ENT inhibitor dipyridamole (grey bars)
or the appropriate concentration of vehicle (black bars). Mean + SEM, n = 8, *P b 0.05.
B and C:MIN6 β-cells (B) andmouse islets (C) that had been transfected with non-silencing
scrambled siRNAs (black bars) or ENT3 siRNAs (grey bars) for 16 h were maintained for
another 24 h in the absence or presence of a cytokine cocktail and caspase 3/7 activities
were measured by a luminescence assay. Mean + SEM, n = 8, ***P b 0.001.
Fig. 6. A: Mouse islets were exposed to green ﬂuorescent nontargeting control siRNAs
(black bar) or ENT3 siRNAs (grey bar) for 36 h and ENT3 mRNA levels were quantiﬁed
by qPCR. Mean + SEM, n = 3, *P b 0.05. B: Groups of three mouse islets that had been
transfected with green ﬂuorescent nontargeting control siRNAs (black bars) or ENT3
siRNAs (grey bars) were incubated in media supplemented with 2 mM glucose, 20 mM
glucose or 20 mM glucose + 500 nM PMA for 1 h and insulin secretion was quantiﬁed
by radioimmunoassay. Mean + SEM, n = 10.
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physiological relevance given the essential role ofmitochondria in cellu-
lar metabolism and the regulation of apoptosis [36–39]. Mitochondria
are known to produce large quantities of adenosine from adenine and
pyridine nucleotides [40] and a mitochondrial equilibrative adenosine
transport system has been identiﬁed that can export adenosine formed
in the mitochondria across the mitochondrial membrane [12]. It
appears that accumulation of mitochondrial adenosine may have dele-
terious effects on cell function since adenosine A1 receptors have been
identiﬁed in mitochondria and A1 receptor deletion is associated with
reductions in apoptotic cell death [41]. These observations suggest
that blocking adenosine's actions via mitochondrial A1 receptors can
protect cells, and it has been proposed that this reduction in apoptosis
was secondary to inhibition of mitochondrial Ca2+ overload and
decreased ROS generation [41].
It has been reported that PHID hENT3mutations causemis-targeting
of mutant ENT3 away from mitochondria and these mutants show
reduced adenosine transport activity [42]. Thus, by inﬂuencing the
concentration of adenosine that is present within mitochondria, ENT3
can regulate mitochondrial function and modiﬁcations in the intra-
mitochondrial nucleoside pool through inactivating mutations may
culminate in deleterious consequences on mitochondria function. It is
therefore possible that depletion of ENT3 in β-cell mitochondria causesexcessive build up of nucleosides that are required for the synthesis of
mtDNA, which in turn causes oxidative stress and inﬂammation associat-
ed with increased mtDNA content, leading to mtDNA damage/mutation
and mitochondrial dysfunction [22,23,43–45]. This theory is supported
by our experimental observations of a 1.7-fold increase in mitochondrial
copy number following siRNAs-mediated knockdown of β-cell ENT3
expression.
To investigate whether perturbation of β-cell ENT3 expression and
the consequent elevation in mtDNA content affected mitochondrial
function, MIN6 β-cell bioenergetics were measured following ENT3
depletion. MIN6 cells have been used in earlier studies formeasurements
of cellular bioenergetics [46,47], which indicated that these cells are an
appropriate model for these experiments. Our studies indicated that
MIN6 β-cells in which ENT3 had been knocked down by transient trans-
fection with siRNAs exhibited signiﬁcantly higher levels of basal respira-
tion, which was caused both by enhanced ATP-linked respiration and
increased proton leak. In addition, oxygen consumption in intracellular
processes that are not associated with mitochondrial respiration (non-
mitochondrial respiration) was also signiﬁcantly elevated following
ENT3 depletion. These ﬁndings suggest that depletion of ENT3 in β-cells
can promote an energy crisis due to increased energy demand and spill-
age of electrons, which is likely to be caused by damage to themitochon-
drial membrane and mitochondrial complexes. Sustained, high energy
demand could lead to the loss of bioenergetic control, and compromised
energy production in mitochondria will trigger apoptotic cell death [48].
In parallel, dysfunctional mitochondria release proteins such as cyto-
chrome C, Smac, EndoG and AIF that activate caspases or induce DNA
fragmentation and chromatin condensation, leading to induction of
apoptosis [36–39]. Furthermore, increased non-mitochondrial respiration
causes additional cytosolic ROS production, whichmay further contribute
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extrinsic and intrinsic pathways [26,27].
The possibility that the alterations in cellular bioenergetics following
ENT3 disruption is associated with enhanced β-cell apoptosis was
investigated using dipyridamole, a global ENT inhibitor that reduces
hENT3-mediated adenosine transport [7,11]. In our experiments the
presence of dipyridamole enhanced β-cell caspase 3/7 activities, suggest-
ing that impairing nucleoside transport via ENTs provokes apoptosis.
However, we found that β-cells also express mRNA encoding ENT1, but
not ENT2, so this increased apoptosis could not be deﬁnitively ascribed
to ENT3 inhibition. ENT3 was therefore speciﬁcally depleted from β-
cells using siRNAs, under the same conditions that were used for the
bioenergetics studies. Under conditions where ENT3 expression was
reduced in MIN6 β-cells there was a signiﬁcant increase in caspase 3/7
activities and experiments performed on mouse islets indicated that
ENT3 knockdown also resulted in enhanced apoptosis, demonstrating
that the cell line data were replicated in primary tissue.
Interestingly, however, knockdown of ENT3 in primary isletswas not
associated with impaired basal or glucose-stimulated insulin release,
nor was secretion in response to the PKC activator PMA compromised.
Although these insulin secretion data are apparently inconsistent with
the observations of mitochondrial dysfunction and enhanced apoptosis
following ENT3 knockdown, there are several possible explanations for
this. First, the extent of knockdown in primary islets was less than in
MIN6 β-cells (36% vs 59%), so the majority of islet cells still had active
ENT3. Second, in the apoptosis experiments caspase 3/7 activities were
only elevated in ENT3-depleted cells after the stress of cytokine expo-
sure, while basal apoptosis was unaffected. Third, it was evident that
some islets that had been exposed to ENT3 siRNAs for 40 h had
fragmented and only whole islets are picked for the secretion experi-
ments, which will not capture potential secretory dysfunction in β-
cells of disrupted islets. It therefore seems likely that reductions in
ENT3 prime the β-cells to enter a cascade of mitochondrial dysfunction
and cellular loss, which will ultimately cause hypoinsulinaemia.
Thus, our data are consistentwith the occurrence of diabetes in indi-
viduals exhibiting loss of function ENT3mutations being a consequence
of impairedmitochondrial nucleoside transport [42], leading to increased
mtDNA expression and mitochondrial dysfunction, which ultimately
leads to the apoptotic loss of β-cells. These experimental observations
are supported by the phenotype of PHID patients and of previously pub-
lishedmitochondrial diabetes syndromes. Thus, PHID is an unusual condi-
tion inwhich insulin-dependent diabetes is autoantibody-negative and is
therefore not secondary to autoimmune destruction of β-cells, as occurs
in archetypal type 1 diabetes. In addition, the age of onset of diabetes in
PHID (median 12 years) is consistent with a gradual loss of β-cell mito-
chondrial homeostasis, ultimately resulting in β-cell apoptosis. Further-
more, some mtDNA mutations show strong associations with diabetes
[49] and there are certain parallels between diabetes in PHID and mito-
chondrial diabetes, whichmost commonly occurs throughmitochondrial
DNA-encoded tRNA genemutations. In these mutant mitochondria there
is disruption of ATP synthesis and progressive reductions in β-cell func-
tion, which ultimately leads to diabetes [50].
In summary, the data presented here, of increased mtDNA copy
number, mitochondrial dysfunction and enhanced apoptosis following
ENT3 depletion, support an important role of ENT3 in maintaining β-
cell number that is lost in PHID.5. Conclusion
We have shown that the equilibrative nucleoside transporter 3
(ENT3) is expressed in β-cell mitochondria and that its depletion
increases mitochondrial DNA content, promotes mitochondrial dysfunc-
tion and induces apoptosis. These effects of ENT3 loss in β-cells may con-
tribute to the aetiology of pigmented hypertrichotic dermatosis with
insulin-dependent diabetes.Author contribution
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